[ <sup>18</sup> F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activityWoo-Suk Kim, Caius G. Radu, Thuc Le et al.|Proceedings of the National Academy of Sciences|2016Cited by 88
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Lazaros J. Lekakis et al.|Blood Cancer Discovery|2023Cited by 49
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphomaSoumya Poddar, Sattva S. Neelapu, Jiali Yan et al.|Journal of Clinical Investigation|2025Cited by 1
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0